Support and Resources for Patients Taking Jakafi Stay up to date with Jakafi Get information and support for understanding polycythemia vera (PV) in adults who have taken a medicine called hydroxyurea and it did not work well enough or was not tolerated.
Can Jakafi be used to treat PV?
...ruxolitinib as a treatment option for patients with PV who have had an inadequate response to or are intolerant of cytoreductive therapy 8 Jakafi is indicated for treatment of PV in adults who have had an inadequate response to or are intolerant of HU.
Why choose incytecares for Jakafi?
At IncyteCARES for Jakafi, our mission is to help eligible patients get started with their medicine and to provide information and support throughout their treatment. We can check with a patient’s insurance plan about their coverage for Jakafi and any out-of-pocket costs required.
What is the indication of Jakafi in the US?
Jakafi is indicated for treatment of PV in adults who have had an inadequate response to or are intolerant of HU. † Estimated total patients treated with commercially available Jakafi in the US since 2011. 9 See Prescribing Information for FDA-approved indications.
Do you need a prescription for Jakafi?
Valid prescription for Jakafi for an FDA-approved indication is required. Patients insured through Medicare Part D, Medicare Advantage, Medicaid, TRICARE, or a state medical assistance program are not eligible. Free product is offered to eligible patients without any purchase contingency or other obligation.
Is Jakafi covered by Medicaid?
Be confirmed as eligible for and enrolled in IncyteCARES for Jakafi. Have commercial prescription drug coverage or a healthcare exchange plan. Patients insured under federal or state government prescription drug programs—including Medicare Part D, Medicare Advantage, Medicaid, or TRICARE—are not eligible.
When will there be a generic for Jakafi?
Jakafi was eligible for patent challenges on November 16, 2015. By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be September 22, 2028.
What tier drug is Jakafi?
Medicare prescription drug plans typically list Jakafi on Tier 5 of their formulary.
Who is the manufacturer of Jakafi?
If you have questions about Jakafi® (ruxolitinib) or Incyte, please contact us via IncyteCARES at 1-855-452-5234. Call your Healthcare Professional about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA.
What is the monthly cost of Jakafi?
As a guide, Jakafi tablets 5 mg usually cost $15,400 for 60 tablets. With NiceRx you will pay a flat monthly fee of $49, regardless of the retail price of your medication.
How long can you take Jakafi?
Jakafi is a long-term treatment. Your Healthcare Professional may allow up to 6 months to see if Jakafi is working for you. If you do not see an improvement after 6 months of treatment, your Healthcare Professional may have you stop taking Jakafi.
Does Jakafi increase platelets?
Jakafi appeared to effectively reduce platelet levels, as well as white blood cell counts and enlarged spleen, in patients with ET who had progressed on or couldn't tolerate Hydrea.
When does Jakafi patent expire?
In the United States, "Jakafi is covered by eight patents, which range in expiration from December 12, 2026 (the earliest expiration date) to June 12, 2028 (the latest expiration date)." Compl.
Can Jakafi cure myelofibrosis?
Jakafi® (ruxolitinib) (JAK-ah-fye) is a prescription medicine available as a pill. Jakafi is used to treat adults with intermediate or high-risk myelofibrosis (MF). Jakafi is the first medicine approved by the Food and Drug Administration (FDA) for the treatment of these patients.
Does Jakafi have a black box warning?
While Opzelura is celebrated as the first topical formulation of a JAK inhibitor to enter the market, its approval comes with a classwide black box warning that has been added to oral JAKs about serious infections, death, cancer, heart-related events and blood clots.
Is ruxolitinib the same as Jakafi?
Low blood counts: Jakafi® (ruxolitinib) may cause low platelet, red blood cell, and white blood cell counts. If you develop bleeding, stop taking Jakafi and call your healthcare provider.
What disease is the opposite of leukemia?
Polycythemia vera (pol-e-sy-THEE-me-uh VEER-uh) is a type of blood cancer. It causes your bone marrow to make too many red blood cells. These excess cells thicken your blood, slowing its flow, which may cause serious problems, such as blood clots. Polycythemia vera is rare.
When does Jakafi go off patent?
In the United States, "Jakafi is covered by eight patents, which range in expiration from December 12, 2026 (the earliest expiration date) to June 12, 2028 (the latest expiration date)." Compl.
When does ruxolitinib patent expire?
Ruxolitinib was authorized likewise by FDA in November 2011 and the US patent is expected to expire in December 2027.
When can a drug become generic?
When patent protection for a brand-name drug expires, the U.S. Food and Drug Administration can approve a generic version of it for sale. The patent protection for a brand-name drug is usually 20 years from the date of the submission of the patent.
Is eliquis going generic in 2022?
As the original manufacturers, they own a patent that prevents generics from being introduced until the patent expires. That patent was extended from February 2023 to November 2026. Both drug makers say that's when generics can be made available.
What to tell your healthcare provider before taking Jakafi?from incytecares.com
Before taking Jakafi, tell your healthcare provider about: all the medications, vitamins, and herbal supplements you are taking and all your medical conditions, including if you have an infection, have or had low white or red blood cell counts, have or had tuberculosis (TB) or have been in close contact with someone who has TB, had shingles (herpes zoster), have or had hepatitis B, have or had liver or kidney problems, are on dialysis, have high cholesterol or triglycerides, had cancer, are a current or past smoker, had a blood clot, heart attack, other heart problems or stroke, or have any other medical condition. Take Jakafi exactly as your healthcare provider tells you. Do not change your dose or stop taking Jakafi without first talking to your healthcare provider.
Where to report Jakafi side effects?from jakafi.com
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088 .
What is jakafi used for?from drugs.com
Jakafi is used to treat adults with certain types of myelofibrosis. Jakafi is also used to treat adults and children 12 years ...
What are the symptoms of Jakafi?from jakafi.com
Tell your healthcare provider if you develop any of the following symptoms of infection: chills, nausea, vomiting, aches, weakness, fever, painful skin rash or blisters. Skin cancers: Some people who take Jakafi have developed certain types of non-melanoma skin cancers.
How much does Jakafi cost?from drugs.com
The cost for Jakafi oral tablet 5 mg is around $15,413 for a supply of 60 tablets, depending on the pharmacy you visit. Prices are for cash paying customers only and are not valid with insurance plans.
How often should I check my cholesterol after taking Jakafi?from incytecares.com
Your healthcare provider will do blood tests to check your cholesterol levels about every 8 to 12 weeks after you start taking Jakafi, and as needed.
Can I take jakafi while pregnant?from incytecares.com
Do not change your dose or stop taking Jakafi without first talking to your healthcare provider. Women should not take Jakafi while pregnant or planning to become pregnant. Do not breastfeed during treatment with Jakafi and for 2 weeks after the final dose.
What to tell your healthcare provider before taking Jakafi?
Before taking Jakafi, tell your healthcare provider about:all the medications, vitamins, and herbal supplements you are taking and all your medical conditions, including if you have an infection, have or had low white or red blood cell counts, have or had tuberculosis (TB) or have been in close contact with someone who has TB, had shingles (herpes zoster), have or had hepatitis B, have or had liver or kidney problems, are on dialysis, have high cholesterol or triglycerides, had cancer, are a current or past smoker, had a blood clot, heart attack, other heart problems or stroke, or have any other medical condition. Take Jakafi exactly as your healthcare provider tells you. Do not change your dose or stop taking Jakafi without first talking to your healthcare provider.
What is Jakafi treatment?
Resources include support info for patients taking Jakafi (ruxolitinib), a treatment for adults with polycythemia vera who did not benefit from or could not tolerate hydroxyurea.
What is Jakafi used for?
Jakafi is a prescription medicine used to treat adults with polycythemia vera who have already taken a medicine called hydroxyurea and it did not work well enough or they could not tolerate it.
Can I take jakafi while pregnant?
Women should not take Jakafi while pregnant or planning to become pregnant. Do not breastfeed during treatment with Jakafi and for 2 weeks after the final dose.
Does Jakafi cause bruising?
The most common side effects of Jakafi include :for certain types of myelofibrosis ( MF) and polycythemia vera ( PV) – low platelet or red blood cell counts , bruising, dizziness, headache, and diarrhea; for acute GVHD – low platelet counts, low red or white blood cell counts, infections, and swelling; and for chronic GVHD – low red blood cell or platelet counts and infections including viral infections.
How often should I check my cholesterol after taking Jakafi?
Your healthcare provider will do blood tests to check your cholesterol levels about every 8 to 12 weeks after you start taking Jakafi, and as needed.
Can Jakafi cause low platelet count?
Low blood counts: Jakafi®(ruxolitinib) may cause low platelet, red blood cell, and white blood cell counts. If you develop bleeding, stop taking Jakafi and call your healthcare provider. Your healthcare provider will do a blood test to check your blood counts before you start Jakafi and regularly during your treatment. Your healthcare provider may change your dose of Jakafi or stop your treatment based on the results of your blood tests. Tell your healthcare provider right away if you develop or have worsening symptoms such as unusual bleeding, bruising, tiredness, shortness of breath, or a fever.
What to tell your healthcare provider before taking Jakafi?
Before taking Jakafi, tell your healthcare provider about: all the medications, vitamins, and herbal supplements you are taking and all your medical conditions, including if you have an infection, have or had low white or red blood cell counts, have or had tuberculosis (TB) or have been in close contact with someone who has TB, had shingles (herpes zoster), have or had hepatitis B, have or had liver or kidney problems, are on dialysis, have high cholesterol or triglycerides, had cancer, are a current or past smoker, had a blood clot, heart attack, other heart problems or stroke, or have any other medical condition. Take Jakafi exactly as your healthcare provider tells you. Do not change your dose or stop taking Jakafi without first talking to your healthcare provider.
What is Jakafi used for?
Jakafi is a prescription medicine used to treat adults with polycythemia vera who have already taken a medicine called hydroxyurea and it did not work well enough or they could not tolerate it.
Does Jakafi cause bruising?
The most common side effects of Jakafi include: for certain types of myelofibrosis (MF) and polycythemia vera (PV) – low platelet or red blood cell counts , bruising, dizziness, headache, and diarrhea; for acute GVHD – low platelet counts, low red or white blood cell counts, infections, and swelling; and for chronic GVHD – low red blood cell or platelet counts and infections including viral infections.
Can Jakafi cause low platelet count?
Low blood counts: Jakafi® (ruxolitinib) may cause low platelet, red blood cell, or white blood cell counts. If you develop bleeding, stop taking Jakafi and call your healthcare provider. Your healthcare provider will do a blood test to check your blood counts before you start Jakafi and regularly during your treatment. Your healthcare provider may change your dose of Jakafi or stop your treatment based on the results of your blood tests. Tell your healthcare provider right away if you develop or have worsening symptoms such as unusual bleeding, bruising, tiredness, shortness of breath, or a fever.
How often should I check my cholesterol after taking Jakafi?
Your healthcare provider will do blood tests to check your cholesterol levels about every 8 to 12 weeks after you start taking Jakafi, and as needed.
Can Jakafi cause blood clots?
Increased risk of blood clots: Blood clots in the veins of your legs (deep vein thrombosis, DVT) or lungs (pulmonary embolism, PE) have happened in people taking another JAK inhibitor for rheumatoid arthritis and may be life-threatening. Tell your healthcare provider right away if you have any signs and symptoms of blood clots during treatment with Jakafi, including: swelling, pain, or tenderness in one or both legs, sudden, unexplained chest or upper back pain, shortness of breath or difficulty breathing
Can Jakafi cause heart attacks?
Increased risk of major cardiovascular events such as heart attack, stroke or death in people who have cardiovascular risk factors and who are current or past smokers while using another JAK inhibitor to treat rheumatoid arthritis: Get emergency help right away if you have any symptoms of a heart attack or stroke while taking Jakafi, including: discomfort in the center of your chest that lasts for more than a few minutes, or that goes away and comes back, severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw, pain or discomfort in your arms, back, neck, jaw, or stomach, shortness of breath with or without chest discomfort, breaking out in a cold sweat, nausea or vomiting, feeling lightheaded, weakness in one part or on one side of your body, slurred speech
What to tell your healthcare provider before taking Jakafi?
Before taking Jakafi, tell your healthcare provider about: all the medications, vitamins, and herbal supplements you are taking and all your medical conditions, including if you have an infection, have or had low white or red blood cell counts, have or had tuberculosis (TB) or have been in close contact with someone who has TB, had shingles (herpes zoster), have or had hepatitis B, have or had liver or kidney problems, are on dialysis, have high cholesterol or triglycerides, had cancer, are a current or past smoker, had a blood clot, heart attack, other heart problems or stroke, or have any other medical condition. Take Jakafi exactly as your healthcare provider tells you. Do not change your dose or stop taking Jakafi without first talking to your healthcare provider.
What is jakafi used for?
Jakafi is used to treat adults with certain types of myelofibrosis.
How often should I check my cholesterol after taking Jakafi?
Your healthcare provider will do blood tests to check your cholesterol levels about every 8 to 12 weeks after you start taking Jakafi, and as needed.
Can Jakafi cause blood clots?
Increased risk of blood clots: Blood clots in the veins of your legs (deep vein thrombosis, DVT) or lungs (pulmonary embolism, PE) have happened in people taking another JAK inhibitor for rheumatoid arthritis and may be life-threatening. Tell your healthcare provider right away if you have any signs and symptoms of blood clots during treatment with Jakafi, including: swelling, pain, or tenderness in one or both legs, sudden, unexplained chest or upper back pain, shortness of breath or difficulty breathing
Can Jakafi cause heart attacks?
Increased risk of major cardiovascular events such as heart attack, stroke or death in people who have cardiovascular risk factors and who are current or past smokers while using another JAK inhibitor to treat rheumatoid arthritis: Get emergency help right away if you have any symptoms of a heart attack or stroke while taking Jakafi, including: discomfort in the center of your chest that lasts for more than a few minutes, or that goes away and comes back, severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw, pain or discomfort in your arms, back, neck, jaw, or stomach, shortness of breath with or without chest discomfort, breaking out in a cold sweat, nausea or vomiting, feeling lightheaded, weakness in one part or on one side of your body, slurred speech
Does Jakafi help with cancer?
Cancer: Some people have had certain types of non-melanoma skin cancers during treatment with Jakafi. Your healthcare provider will regularly check your skin during your treatment with Jakafi. Tell your healthcare provider if you develop any new or changing skin lesions during treatment with Jakafi.
Can Jakafi cause a fever?
Infection: You may be at risk for developing a serious infection during treatment with Jakafi. Tell your healthcare provider if you develop any of the following symptoms of infection: chills, nausea, vomiting, aches, weakness, fever, painful skin rash or blisters.
What to tell your healthcare provider before taking Jakafi?from jakafi.com
Before taking Jakafi, tell your healthcare provider about: all the medications, vitamins, and herbal supplements you are taking and all your medical conditions, including if you have an infection, have or had tuberculosis (TB) or have been in close contact with someone who has TB, have or had hepatitis B, have or had liver or kidney problems, are on dialysis, have high cholesterol or triglycerides, had skin cancer, or have any other medical condition. Take Jakafi exactly as your healthcare provider tells you. Do not change your dose or stop taking Jakafi without first talking to your healthcare provider.
What is Jakafi treatment?from jakafi.com
It is a targeted treatment that works to help keep the production of blood cells under control. Discover what may be possible with Jakafi for the treatment of polycythemia vera in patients who did not benefit from HU.
How does Jakafi work?from jakafi.com
JAK proteins send signals that affect the production of blood cells in the bone marrow (A). When JAKs send too many signals , they cause the body to make the wrong number of blood cells. This chain of events is called overactive JAK signaling (B) .
What are possible side effects of Jakafi?from jakafi.com
Your healthcare provider will perform blood tests to check your blood counts before you start Jakafi and regularly during your treatment. Your healthcare provider may change your dose of Jakafi or stop your treatment based on the results of your blood tests. Tell your healthcare provider right away if you develop or have worsening symptoms such as unusual bleeding, bruising, tiredness, shortness of breath, or a fever.
What is a JAK mutation?from jakafi.com
One way is by a JAK mutation. A mutation is a small change in the DNA that causes proteins to act differently than normally intended. All people with PV are believed to have overactive JAK signaling even if they do not have a JAK mutation.
Can you change your dose of Jakafi?from jakafi.com
Your healthcare provider will perform blood tests to check your blood counts before you start Jakafi and regularly during your treatment. Your healthcare provider may change your dose of Jakafi or stop your treatment based on the results of your blood tests.
Does Jakafi cause cancer?from jakafi.com
Skin cancers: Some people who take Jakafi have developed certain types of non-melanoma skin cancers. Tell your healthcare provider if you develop any new or changing skin lesions. Increases in cholesterol: You may have changes in your blood cholesterol levels.
How Jakafi Copay Assistance Works
Our team of expert billers finds the best avenues of coverage that minimize out-of-pocket costs.
What Is Jakafi Used For?
Myelofibrosis: Jakafi is indicated for the treatment of intermediate or high-risk myelofibrosis (MF). This includes primary MF, post-polycythemia vera MF and post-essential thrombocythemia MF in adults.
What is the PAP number for Jakafi?
For more information, call IncyteCARES at 1-855-452-5234, Monday through Friday, 8 am –8 pm ET. The IncyteCARES Patient Assistance Program (PAP) helps eligible patients who do not have prescription drug insurance or who have trouble affording their copay for Jakafi. No purchase contingencies or other obligations apply.
What is Jakafi used for?
Jakafi is indicated for treatment of steroid-refractory acute graft-versus-host disease (aGVHD) in adult and pediatric patients 12 years and older .
How long does it take for myelofibrosis to return after Jakafi?
When discontinuing Jakafi, myeloproliferative neoplasm-related symptoms may return within one week. After discontinuation, some patients with myelofibrosis have experienced fever, respiratory distress, hypotension, DIC, or multi-organ failure. If any of these occur after discontinuation or while tapering Jakafi, evaluate and treat any intercurrent illness and consider restarting or increasing the dose of Jakafi. Instruct patients not to interrupt or discontinue Jakafi without consulting their physician. When discontinuing or interrupting Jakafi for reasons other than thrombocytopenia or neutropenia, consider gradual tapering rather than abrupt discontinuation
What are the most common nonhematologic adverse reactions in myelofibrosis?
In myelofibrosis and polycythemia vera, the most common nonhematologic adverse reactions (incidence ≥15%) were bruising, dizziness, headache, and diarrhea. In acute graft-versus-host disease, the most common nonhematologic adverse reactions (incidence >50%) were infections (pathogen not specified) and edema. In chronic graft-versus-host disease, the most common nonhematologic adverse reactions (incidence ≥20%) were infections (pathogen not specified) and viral infections
How to manage thrombocytopenia?
Manage thrombocytopenia by reducing the dose or temporarily interrupting Jakafi. Platelet transfusions may be necessary
Can you take jakafi for TB?
Tuberculosis (TB) infection has been reported. Observe patients taking Jakafi for signs and symptoms of active TB and manage promptly. Prior to initiating Jakafi, evaluate patients for TB risk factors and test those at higher risk for latent infection. Consult a physician with expertise in the treatment of TB before starting Jakafi in patients with evidence of active or latent TB. Continuation of Jakafi during treatment of active TB should be based on the overall risk-benefit determination
How much of FPL is eligible for Medicare Part D?
OR. Medicare Part D patients may be eligible by meeting additional criteria and program requirements, including but not limited to earning less than 600% of the FPL. HOW TO ENROLL YOUR PATIENTS.
What is the Patient Advocate Foundation?
Patient Advocate Foundation provides financial assistance to qualified patients assisting them with prescription drug co-payments their insurance requires relative to their diagnosis as well as arbitration, mediation, and negotiation services .
What is PV Reporter?
Founder of PV Reporter, a resource for Myeloproliferative Neoplasm (MPN) patients and caregivers. After being diagnosed with Polycythemia Vera (PV) in 2009, I utilized social media to connect with "informed patients" and develop a better understanding of emerging treatment options. My philosophy on patient care is straight forward - "educating the patient is essential, so the patient can guide their physician to meet his or her needs." PV Reporter is a comprehensive resource hub giving visitors vital tools to become "empowered patients."
What is Air Care Alliance?
Air Care Alliance (ACA) provides a listing of nonprofit organizations nationwide that fly patients to treatments at no charge.
